Provectus Biopharmaceuticals filings document governance, capital-structure actions, and material-event disclosures for a clinical-stage biotechnology issuer focused on rose bengal sodium-based medicines. Proxy materials cover annual-meeting voting matters, board elections, stock ownership, director and officer interests, and related-party transaction disclosures.
Form 8-K reports record corporate events such as annual-meeting announcements and amendments to the certificates of designation for Series D and Series D-1 Convertible Preferred Stock. These filings also describe preferred-stock conversion terms, common-stock implications, exhibit filings, and the company’s use of press releases to furnish updates tied to public-company reporting.
Provectus Biopharmaceuticals, Inc. files its 2025 annual report outlining a broad rose bengal sodium (RBS)–based immunotherapy platform, spanning oncology, dermatology, ophthalmology and multiple early non-clinical programs. The company highlights an extensive U.S. and international patent estate supporting its pharmaceutical-grade RBS and PV‑10/PH‑10 candidates.
The report warns of substantial doubt about the company’s ability to continue as a going concern, citing an accumulated net loss of approximately $263 million since inception, a cash balance of $251,291 and a working capital deficit of $6,329,503 as of December 31, 2025. Management states that additional capital will be required in 2026 and beyond to advance clinical trials and operations.
As of June 30, 2025, the aggregate market value of common equity held by non‑affiliates was $30,585,685, based on a price of $0.075 per share. There were 420,279,879 shares of common stock outstanding as of March 23, 2026. The company also discloses cybersecurity, environmental and human‑capital practices, including a six‑person full‑time workforce and use of cloud‑based, third‑party monitored IT systems.
PROVECTUS BIOPHARMACEUTICALS, INC. CEO Edward Pershing reported non‑market transactions converting debt and preferred equity into common stock. An 8% unsecured convertible promissory note converted into 49,067 shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per share. Those 49,067 Series D-1 shares were then converted into 490,670 shares of common stock, reflecting the 10:1 conversion ratio. Following these conversions, Pershing directly holds 2,710,054 shares of common stock. The Series D-1 Preferred Stock is also described as automatically converting into common stock on December 31, 2028 unless converted earlier under its terms.
PROVECTUS BIOPHARMACEUTICALS, INC. CEO Edward Pershing reported receiving an 8% unsecured convertible promissory note. The note allows him to convert outstanding principal and interest into shares of Series D-1 Convertible Preferred Stock at $2.862 per share, with automatic conversion into Series D-1 Preferred twelve months after the issue date. Each Series D-1 Preferred share is convertible into 10 shares of common stock, and the preferred stock will automatically convert into common stock on December 31, 2028 unless converted earlier under its terms.
PROVECTUS BIOPHARMACEUTICALS, INC. CEO Edward Pershing reported acquiring an 8% unsecured convertible promissory note as a derivative security. The note was issued under the company’s 2025 Financing and does not immediately involve common shares, but it can later convert into equity.
The footnotes state that the outstanding principal and interest of the note may be converted into shares of Series D-1 Convertible Preferred Stock at a price per share of $2.862, either voluntarily at any time or automatically twelve months after the issue date. Each Series D-1 Preferred share is in turn convertible into 10 shares of common stock and will automatically convert into common stock on December 31, 2028 unless converted earlier under its terms.
PROVECTUS BIOPHARMACEUTICALS, INC. director and CEO Edward Pershing reported the grant of an 8% unsecured convertible promissory note. The note may be voluntarily converted into shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per share while it is outstanding.
The outstanding principal and interest will automatically convert into Series D-1 Preferred Stock at $2.862 per share twelve months after the note’s issue date. Each share of Series D-1 Preferred Stock is convertible into 10 shares of common stock, and the preferred stock will automatically convert into common stock on December 31, 2028 unless converted earlier.
PROVECTUS BIOPHARMACEUTICALS, INC. CEO Edward Pershing reported a non-cash conversion of an 8% unsecured convertible promissory note into 47,180 shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per share on February 20, 2026.
Each Series D-1 Preferred share is convertible into 10 common shares and will automatically convert into common stock on December 31, 2028, unless converted earlier under its certificate of designation. Following this transaction, Pershing directly owned 2,660,987 Series D-1 Preferred shares.
Provectus Biopharmaceuticals CEO Edward Pershing reported receiving an 8% unsecured convertible promissory note. This derivative security allows him to convert the note’s outstanding principal and interest into shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per share at any time while the note is outstanding.
The footnotes state that, twelve months after the note’s issue date, the outstanding principal and interest will automatically convert into Series D-1 Preferred Stock at the same $2.862 conversion price. Each Series D-1 Preferred share is then convertible into 10 shares of Provectus common stock and will automatically convert into common stock on December 31, 2028, unless converted earlier under its terms.
Provectus Biopharmaceuticals CEO Edward Pershing reported acquiring an 8% unsecured convertible promissory note from the company on February 12, 2026. The note has a principal amount of $30,000 and may be converted into Series D-1 Convertible Preferred Stock at $2.862 per share.
The outstanding principal and interest on the note will automatically convert into Series D-1 preferred stock twelve months after the note’s issue date. Each Series D-1 preferred share is convertible into 10 shares of common stock and will automatically convert into common stock on December 31, 2028 unless converted earlier under its terms.
Pershing Edward reported open-market purchase transactions in a Form 4 filing for PVCT. The filing lists transactions totaling 34,940 shares at a weighted average price of $2.86 per share. Following the reported transactions, holdings were 2,613,807 shares.
Provectus Biopharmaceuticals CEO Edward Pershing, who also serves as a director, reported receiving an 8% unsecured convertible promissory note on February 5, 2026. The note can be converted into shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per share.
Under the terms described, each share of Series D-1 preferred is convertible into 10 shares of common stock. The Series D-1 preferred will automatically convert into common stock on December 31, 2028, unless it is converted earlier under its certificate of designation.